193 related articles for article (PubMed ID: 19112015)
21. AGE-modified basement membrane cooperates with Endo180 to promote epithelial cell invasiveness and decrease prostate cancer survival.
Rodriguez-Teja M; Gronau JH; Breit C; Zhang YZ; Minamidate A; Caley MP; McCarthy A; Cox TR; Erler JT; Gaughan L; Darby S; Robson C; Mauri F; Waxman J; Sturge J
J Pathol; 2015 Mar; 235(4):581-92. PubMed ID: 25408555
[TBL] [Abstract][Full Text] [Related]
22. The collagen receptor uPARAP/Endo180.
Engelholm LH; Ingvarsen S; Jürgensen HJ; Hillig T; Madsen DH; Nielsen BS; Behrendt N
Front Biosci (Landmark Ed); 2009 Jan; 14(6):2103-14. PubMed ID: 19273187
[TBL] [Abstract][Full Text] [Related]
23. Targeting uPA/uPAR in prostate cancer.
Li Y; Cozzi PJ
Cancer Treat Rev; 2007 Oct; 33(6):521-7. PubMed ID: 17658220
[TBL] [Abstract][Full Text] [Related]
24. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
25. uPARAP/Endo180: a multifaceted protein of mesenchymal cells.
Gucciardo F; Pirson S; Baudin L; Lebeau A; Noël A
Cell Mol Life Sci; 2022 Apr; 79(5):255. PubMed ID: 35460056
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
[TBL] [Abstract][Full Text] [Related]
27. Urokinase-type plasminogen activator negatively regulates α-smooth muscle actin expression via Endo180 and the uPA receptor in corneal fibroblasts.
Sugioka K; Nishida T; Kodama-Takahashi A; Murakami J; Mano F; Okada K; Fukuda M; Kusaka S
Am J Physiol Cell Physiol; 2022 Jul; 323(1):C104-C115. PubMed ID: 35649252
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer.
Stearns ME; Stearns M
Oncol Res; 1996; 8(2):63-7. PubMed ID: 8859776
[TBL] [Abstract][Full Text] [Related]
29. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
31. Tumor-associated Endo180 requires stromal-derived LOX to promote metastatic prostate cancer cell migration on human ECM surfaces.
Caley MP; King H; Shah N; Wang K; Rodriguez-Teja M; Gronau JH; Waxman J; Sturge J
Clin Exp Metastasis; 2016 Feb; 33(2):151-65. PubMed ID: 26567111
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of the leptin and leptin receptor expressions in prostate tissues.
Hoon Kim J; Lee SY; Myung SC; Kim YS; Kim TH; Kim MK
Asian J Androl; 2008 Nov; 10(6):923-8. PubMed ID: 18958356
[TBL] [Abstract][Full Text] [Related]
33. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy.
Curino AC; Engelholm LH; Yamada SS; Holmbeck K; Lund LR; Molinolo AA; Behrendt N; Nielsen BS; Bugge TH
J Cell Biol; 2005 Jun; 169(6):977-85. PubMed ID: 15967816
[TBL] [Abstract][Full Text] [Related]
34. Urokinase receptor variants in tissue and body fluids.
Høyer-Hansen G; Lund IK
Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
[TBL] [Abstract][Full Text] [Related]
35. Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
[TBL] [Abstract][Full Text] [Related]
36. Increased aggressiveness of human prostate PC-3 tumor cells expressing cell surface localized membrane type-1 matrix metalloproteinase (MT1-MMP).
Wang X; Wilson MJ; Slaton JW; Sinha AA; Ewing SL; Pei D
J Androl; 2009; 30(3):259-74. PubMed ID: 19136391
[TBL] [Abstract][Full Text] [Related]
37. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
38. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.
Azoulay S; Terry S; Chimingqi M; Sirab N; Faucon H; Gil Diez de Medina S; Moutereau S; Maillé P; Soyeux P; Abbou C; Salomon L; Vacherot F; de La Taille A; Loric S; Allory Y
J Pathol; 2008 Dec; 216(4):460-70. PubMed ID: 18825689
[TBL] [Abstract][Full Text] [Related]
39. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry.
Trudel D; Fradet Y; Meyer F; Harel F; Têtu B
Hum Pathol; 2008 May; 39(5):731-9. PubMed ID: 18329693
[TBL] [Abstract][Full Text] [Related]
40. Posttranscriptional regulation of urokinase receptor expression by heterogeneous nuclear ribonuclear protein C.
Velusamy T; Shetty P; Bhandary YP; Liu MC; Shetty S
Biochemistry; 2008 Jun; 47(24):6508-17. PubMed ID: 18494499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
